| 6 Aug 2026, 20:09 | Bioshares Biotech Summit Presentation | Presentations | — | 03026 |
| 4 Aug 2026, 18:22 | Amplia signs Collaboration and Supply Agreement with Lilly | Company Update | MS | 11001 |
| 31 July 2026, 18:33 | Scientific Paper Studies of narmafotinib - Pancreatic Cancer | Company Update | — | 11001 |
| 29 July 2026, 18:29 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19001, 19006 |
| 28 July 2026, 02:14 | Notice of Annual General Meeting/Proxy Form | Meetings & Governance | — | 08001, 08004 |
| 16 July 2026, 04:27 | Notification regarding unquoted securities - ATX | Other | — | 06021 |
| 16 July 2026, 04:18 | Notification regarding unquoted securities - ATX | Other | — | 06021 |
| 13 July 2026, 19:37 | Amplia Therapeutics Shareholder Webinar | Presentations | — | 14014 |
| 7 July 2026, 02:43 | Initial Director's Interest Notice - Brett Carter | Director Interests | — | 02008 |
| 6 July 2026, 18:52 | Amplia Announces Appointment of Brett Carter to Board | Company Administration | — | 12001 |
| 1 July 2026, 18:20 | Annual General Meeting to be held Friday 28 August 2026 | Meetings & Governance | — | 08006 |
| 30 June 2026, 18:18 | Amplia Announces Changes to Board's Leadership Roles | Other | — | 12017 |
| 25 June 2026, 18:17 | Notice of Initial Substantial Holding from SOL | Substantial Holders | — | 02001 |
| 25 June 2026, 00:51 | Becoming a substantial holder from PCG | Substantial Holders | — | 02001 |
| 30 May 2026, 01:38 | Appendix 4G - Key to Corporate Governance Disclosures | Company Administration | — | 03025 |
| 29 May 2026, 23:43 | Corporate Governance Statement 2026 | Company Administration | — | 03024 |
| 29 May 2026, 23:37 | Preliminary Final Report and Annual Report YE 31 March 2026 | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 |
| 19 May 2026, 18:18 | Amplia Launches First Stage of Pivotal Narmafotinib Trial | Company Update | MS | 11001 |
| 13 May 2026, 01:49 | Notice under Section 708A(5)(e) of the Corporations Act | Securities Administration | — | 06018 |
| 13 May 2026, 01:28 | Application for quotation of securities - ATX | Other | — | 06020 |
| 8 May 2026, 18:29 | Amplia and ANZGOG announce Ovarian Cancer Study | Company Update | MS | 11001 |
| 28 Apr 2026, 19:38 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19004, 19009 |
| 22 Apr 2026, 18:26 | ACCENT Trial Mature Data Presented at AACR Conference | Presentations | — | 03026 |
| 9 Apr 2026, 00:06 | Amplia MD Responds to Questions Regarding AMPLICITY Trial | Presentations | — | 14014 |
| 7 Apr 2026, 18:40 | Amplia Therapeutics Halts Recruitment in AMPLICITY Trial | Company Update | MS | 11001 |
| 23 Mar 2026, 20:35 | Amplia Reports Improved Responses & Survival in ACCENT trial | Company Update | MS | 09014, 11001 |
| 19 Mar 2026, 21:57 | Trading Halt | Trading Halt / Suspension | MS | 09007 |
| 19 Mar 2026, 20:52 | Pause in Trading | Trading Halt / Suspension | MS | 09005 |
| 9 Mar 2026, 19:14 | Benefit of Narmafotinib in kRas-Mutated Cancer Models | Company Update | — | 11001 |
| 25 Feb 2026, 19:10 | Appointment of Chief Financial Officer | Company Administration | — | 12008 |
| 18 Feb 2026, 19:11 | Amplia Emergence 2026 Conference Presentation | Presentations | — | 03026 |
| 11 Feb 2026, 20:09 | US Sites For AMPLICITY Pancreatic Cancer Trial Open | Company Update | — | 11001 |
| 30 Jan 2026, 19:28 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19003, 19008 |
| 23 Jan 2026, 03:44 | Change in substantial holding | Substantial Holders | — | 02002 |
| 22 Jan 2026, 19:21 | Narmafotinib Large-Scale Manufacture Complete | Company Update | — | 11001 |
| 10 Jan 2026, 03:20 | ACCENT Data Presented at 2026 ASCO GI Cancer Symposium | Company Update | — | 11001 |
| 19 Dec 2025, 19:26 | Amplia Enters 2nd Agreement with Drug Screening Co Next Bio | Company Update | — | 11001 |
| 12 Dec 2025, 06:56 | Additional Confirmed Response Reported-Investor Presentation | Presentations | — | 03026 |
| 3 Dec 2025, 19:30 | Key narmafotinib Patent Granted in the US | Company Update | — | 11001 |
| 28 Nov 2025, 03:44 | Half Yearly Report and Accounts | Financial Results | MS | 03004, 03009, 03010, 03015, 03019 |
| 20 Nov 2025, 20:59 | Positive Response from US FDA to Amplia's Type D Meeting | Company Update | MS | 11001 |
| 11 Nov 2025, 03:42 | Notification regarding unquoted securities - ATX | Other | — | 06021 |
| 31 Oct 2025, 19:19 | Amplia Commences Trading on U.S. OTCQB Venture Market | Securities Administration | — | 14011 |
| 29 Oct 2025, 20:03 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19002, 19007 |
| 28 Oct 2025, 20:13 | Amplia Receives R&D Tax Rebate Totalling $3.77 Million | Periodic Reports | MS | 03014 |
| 17 Oct 2025, 21:33 | Amplia Therapeutics to Significantly Expand U.S. Presence | Company Update | — | 11001 |
| 9 Oct 2025, 19:24 | ADDITIONAL RESPONSES IN ACCENT PANCREATIC CANCER TRIAL | Company Update | — | 11001 |
| 8 Oct 2025, 20:48 | Notification of cessation of securities - ATX | Other | — | 06027 |
| 30 Sept 2025, 18:36 | Patent Allowance for Key Narmafotinib Patent in US | Company Update | — | 11001 |
| 8 Sept 2025, 22:22 | Change of Director's Interest Notice - Warwick Tong | Director Interests | — | 02009 |